{"title":"法莫替丁在帕金森病治疗中的应用:一项初步研究。","authors":"S P Molinari, R Kaminski, A Di Rocco, M D Yahr","doi":"10.1007/BF02259665","DOIUrl":null,"url":null,"abstract":"<p><p>Seven patients with idiopathic Parkinson's disease were enrolled in a ten week study to evaluate the efficacy of famotidine, an histamine H2-antagonist, in the treatment of bradyphrenia. Patients received famotidine 80 mg/day for a period of six weeks and were evaluated with neuropsychological tests. Overall, patients demonstrated improvement in variables measured. Some patients also reported an improvement in their motor symptoms.</p>","PeriodicalId":16466,"journal":{"name":"Journal of Neural Transmission - Parkinson's Disease and Dementia Section","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02259665","citationCount":"29","resultStr":"{\"title\":\"The use of famotidine in the treatment of Parkinson's disease: a pilot study.\",\"authors\":\"S P Molinari, R Kaminski, A Di Rocco, M D Yahr\",\"doi\":\"10.1007/BF02259665\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Seven patients with idiopathic Parkinson's disease were enrolled in a ten week study to evaluate the efficacy of famotidine, an histamine H2-antagonist, in the treatment of bradyphrenia. Patients received famotidine 80 mg/day for a period of six weeks and were evaluated with neuropsychological tests. Overall, patients demonstrated improvement in variables measured. Some patients also reported an improvement in their motor symptoms.</p>\",\"PeriodicalId\":16466,\"journal\":{\"name\":\"Journal of Neural Transmission - Parkinson's Disease and Dementia Section\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1995-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/BF02259665\",\"citationCount\":\"29\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neural Transmission - Parkinson's Disease and Dementia Section\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF02259665\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neural Transmission - Parkinson's Disease and Dementia Section","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02259665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The use of famotidine in the treatment of Parkinson's disease: a pilot study.
Seven patients with idiopathic Parkinson's disease were enrolled in a ten week study to evaluate the efficacy of famotidine, an histamine H2-antagonist, in the treatment of bradyphrenia. Patients received famotidine 80 mg/day for a period of six weeks and were evaluated with neuropsychological tests. Overall, patients demonstrated improvement in variables measured. Some patients also reported an improvement in their motor symptoms.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
